Patents by Inventor Andrew David Cansfield

Andrew David Cansfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CGRP ANTAGONIST COMPOUNDS
    Publication number: 20220306651
    Abstract: The disclosures herein relate to novel compounds of Formula (1): and salts thereof, wherein A1, A2, Q, X, R1, R2 and R3 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 29, 2022
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Stephen Paul Watson, Julie Cansfield, Michael Alistair O'Brien, Francesca Deflorian, Gregory R. Ott, Nigel Alan Swain, Andrew David Cansfield, John Andrew Christopher, Andrea Bortolato
  • CGRP ANTAGONIST COMPOUNDS
    Publication number: 20220251110
    Abstract: The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, R1 and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 11, 2022
    Inventors: Giles Albert Brown, Miles Stuart Congreve, Stephen Paul Watson, Julie Cansfield, Michael Alistair O'Brien, Francesca Deflorian, Gregory R. Ott, Nigel Alan Swain, Andrew David Cansfield
  • Morpholino substituted urea derivatives as mTOR inhibitors
    Patent number: 9249129
    Abstract: The invention relates to compounds of formula (I) wherein X1, X2, R1 to R4, m, and n have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including the compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: February 2, 2016
    Assignee: CELLZOME LIMITED
    Inventors: Jessica Taylor, Daniel Paul Hardy, Rosemary Lynch, Helen Sarah Niblock, Andrew David Cansfield
  • Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
    Patent number: 9242993
    Abstract: The invention relates to compounds of formula (I) wherein m, o, Ra, Rb, R1 and T1 have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including the compounds, the preparation of the compounds as well as their use as medicaments.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: January 26, 2016
    Assignee: CELLZOME LIMITED
    Inventors: Rosemary Lynch, Andrew David Cansfield, Daniel Paul Hardy, John Thomas Feutrill, Rita Adrego, Katie Ellard, Tammy Ladduwahetty
  • Morpholino substituted urea or carbamate derivatives as MTOR inhibitors
    Patent number: 9175011
    Abstract: The invention relates to compounds of formula (I) wherein m, n, R1, T0 and T1 have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds as well as methods of treating mTOR related diseases.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: November 3, 2015
    Assignee: CELLZONE LIMITED
    Inventors: Rosemary Lynch, Andrew David Cansfield, Daniel Paul Hardy, Mihiro Sunose, Adeline Morel, Laura Convery, Rita Adrego
  • MORPHOLINO SUBSTITUTED UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS
    Publication number: 20140378438
    Abstract: The invention relates to compounds of formula (I) wherein m, n, R1, T0 and T1 have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds as well as methods of treating mTOR related diseases.
    Type: Application
    Filed: September 21, 2012
    Publication date: December 25, 2014
    Applicant: CELLZOME LIMITED
    Inventors: Rosemary Lynch, Andrew David Cansfield, Daniel Paul Hardy, Mihiro Sunose, Adeline Morel, Laura Convery, Rita Adrego
  • Amino triazoles as PI3K inhibitors
    Patent number: 8865699
    Abstract: The invention relates to compounds of formula (I) wherein X, T1 and R1 to R3 have the meaning as cited in the description and the claims. Said compounds are useful as protein kinase inhibitors, especially inhibitors of PI3K, for the treatment or prophylaxis of immunological, inflammatory, autoimmune, or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: October 21, 2014
    Assignee: Cellzome Ltd.
    Inventors: Nigel Ramsden, Kathryn Bell, Andrew David Cansfield, Jess Taylor, Mihiro Sunose, David Middlemiss, Gitte Neubauer
  • PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS
    Publication number: 20140296234
    Abstract: The invention relates to compounds of formula (I) wherein X, R1, R2, T, m, n, o have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Application
    Filed: June 13, 2014
    Publication date: October 2, 2014
    Inventors: Rosemary LYNCH, Andrew David CANSFIELD, Helen Sarah NIBLOCK, Daniel HARDY, Jane Elizabeth SCANLON, Rita ADREGO, Nigel RAMSDEN
  • MORPHOLINO SUBSTITUTED BICYCLIC PYRIMIDINE UREA OR CARBAMATE DERIVATIVES AS MTOR INHIBITORS
    Publication number: 20140288066
    Abstract: The invention relates to compounds of formula (I) wherein m, o, Ra, Rb, R1 and T1 have the meaning as cited in the description and the claims. The compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including the compounds, the preparation of the compounds as well as their use as medicaments.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 25, 2014
    Inventors: Rosemary Lynch, Andrew David Cansfield, Daniel Paul Hardy, John Thomas Feutrill, Rita Adrego, Katie Ellard, Tammy Ladduwahetty
  • Pyrimidine derivatives as mTOR inhibitors
    Patent number: 8785457
    Abstract: The invention relates to compounds of formula (I) wherein X, R1, R2, T, m, n, o have the meaning as cited in the description and the claims. The compounds of formula (I) are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: July 22, 2014
    Assignee: Cellzome Limited
    Inventors: Rosemary Lynch, Andrew David Cansfield, Helen Sarah Niblock, Daniel Hardy, Jane Elizabeth Scanlon, Rita Adrego, Nigel Ramsden
  • DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS
    Publication number: 20140163023
    Abstract: The invention relates to compounds of formula (I) wherein X, R1, R2, T0, o have the meaning as cited in the description and the claims. The compounds of formula I are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including the compounds of formula I, the preparation of such compounds as well as the use as medicaments.
    Type: Application
    Filed: April 2, 2012
    Publication date: June 12, 2014
    Applicant: Cellzome Limited
    Inventors: Rosemary Lynch, Andrew David Cansfield, Daniel Paul Hardy, Jane Elizabeth Scanlon, Rita Joana Rodrigues Adrego
  • MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS
    Publication number: 20130196982
    Abstract: The invention relates to compounds of formula (I) wherein X1, X2, R1 to R4, m, n have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Application
    Filed: March 4, 2011
    Publication date: August 1, 2013
    Inventors: Rosemary Lynch, Andrew David Cansfield, Helen Sarah Niblock, Daniel Paul Hardy, Jessica Taylor
  • PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
    Publication number: 20120065202
    Abstract: The invention relates to compounds of formula (I) wherein X, R1, R2, T, m, n, o have the meaning as cited in the description and the claims. Said compounds are useful as inhibitors of mTOR for the treatment or prophylaxis of mTOR related diseases and disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.
    Type: Application
    Filed: March 12, 2010
    Publication date: March 15, 2012
    Inventors: Rosemary Lynch, Andrew David Cansfield, Helen Sarah Niblock, Daniel Hardy, Jane Elizabeth Scanlon, Rita Adrego, Nigel Ramsden
  • AMINO TRIAZOLES AS PI3K INHIBITORS
    Publication number: 20110021497
    Abstract: The invention relates to compounds of formula (I) wherein X, T1 and R1 to R3 have the meaning as cited in the description and the claims. Said compounds are useful as protein kinase inhibitors, especially inhibitors of PI3K, for the treatment or prophylaxis of immunological, inflammatory, autoimmune, or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.
    Type: Application
    Filed: November 21, 2008
    Publication date: January 27, 2011
    Inventors: Nigel Ramsden, Kathryn Bell, Andrew David Cansfield, Jess Taylor, Mihiro Sunose, David Middlemiss, Gitte Neubauer